Constructing a hybrid molecule with low capacity of IgE binding from Chenopodium album pollen allergens

Immunology Letters

Volumn 144, Issue 1-2, 2012, Pages 67-77

  Nouri, Hamid Reza ^a   Varasteh, Abdolreza ^b   Vahedi, Fatemeh ^c   Chamani, Jamshidkhan ^d   Afsharzadeh, Danial ^a   Sankian, Mojtaba ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c RAZI VACCINE AND SERUM RESEARCH INSTITUTE   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Chenopodium album pollen; Hybrid molecule; Recombinant allergen; Specific immunotherapy

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN E; POLLEN ANTIGEN; RECOMBINANT ALLERGEN;

ADULT; AFFINITY CHROMATOGRAPHY; ARTICLE; CHENOPODIUM ALBUM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GENETIC ENGINEERING; HUMAN; IMMUNOREACTIVITY; MALE; MOLECULAR HYBRIDIZATION; POLLEN ALLERGY; PRICK TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN MANIFESTATION; SKIN TEST; WESTERN BLOTTING;

ALLERGENS; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, PLANT; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; CHENOPODIUM ALBUM; DESENSITIZATION, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ENGINEERING; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; POLLEN; RECOMBINANT FUSION PROTEINS; SKIN TESTS;

EID: 84860350178     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.03.008     Document Type: Article

References (34)

1. Gerth van Wijk R. Allergy: a global problem. Qual Life. Allergy 2002, 57:1097-1110.
2. Asher M.I., Montefort S., Bjorksten B., Lai C.K., Strachan D.P., Weiland S.K., et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006, 368:733-743.
3. Durham S.R. Allergen immunotherapy (desensitisation) for allergic diseases. Clin Med 2006, 6:348-351.
4. Larche M., Akdis C.A., Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006, 6:761-771.
5. Bhalla P.L., Singh M.B. Biotechnology-based allergy diagnosis and vaccination. Trends Biotechnol 2008, 26:153-161.
6. Moverare R., Elfman L., Vesterinen E., Metso T., Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002, 57:423-430.
7. Valenta R., Kraft D. Recombinant allergens: from production and characterization to diagnosis, treatment, and prevention of allergy. Methods 2004, 32:207-208.
8. Valenta R., Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007, 119:826-830.
9. Vrtala S., Focke-Tejkl M., Swoboda I., Kraft D., Valenta R. Strategies for converting allergens into hypoallergenic vaccine candidates. Methods 2004, 32:313-320.
10. Bordignon V., Burastero S.E. Age, gender and reactivity to allergens independently influence skin reactivity to histamine. J Investig Allergol Clin Immunol 2006, 16:129-135.
11. Linhart B., Valenta R. Vaccine engineering improved by hybrid technology. Int Arch Allergy Immunol 2004, 134:324-331.
12. Bonura A., Corinti S., Artale A., Di Felice G., Amoroso S., Melis M., et al. A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination. Int Arch Allergy Immunol 2007, 142:274-284.
13. Barderas R., Villalba M., Lombardero M., Rodriguez R. Identification and characterization of Che a 1 allergen from Chenopodium album pollen. Int Arch Allergy Immunol 2002, 127:47-54.
14. Fereidouni M., Hossini R.F., Azad F.J., Assarehzadegan M.A., Varasteh A. Skin prick test reactivity to common aeroallergens among allergic rhinitis patients in Iran. Allergol Immunopathol (Madr) 2009, 37:73-79.
15. Barderas R., Villalba M., Pascual C.Y., Batanero E., Profilin Rodriguez R. (Che a 2) and polcalcin (Che a 3) are relevant allergens of Chenopodium album pollen: isolation, amino acid sequences, and immunologic properties. J Allergy Clin Immunol 2004, 113:1192-1198.
16. Barderas R., Villalba M., Rodriguez R. Che a 1: recombinant expression, purification and correspondence to the natural form. Int Arch Allergy Immunol 2004, 135:284-292.
17. Amini A., sankian M., Assarehzadegan M.A., Vahedi F., Varasteh A. Chenopodium album pollen profilin (Che a 2): homology modeling and evaluation of cross-reactivity with allergenic profilins based on predicted potential IgE epitopes and IgE reactivity analysis. Mol Biol Rep 2011, 38:2579-2587.
18. Vahedi F., Sankian M., Moghadam M., Mohaddesfar M., Ghobadi S., Varasteh A.R. Cloning and expression of Che a 1, the major allergen of Chenopodium album in Escherichia coli. Appl Biochem Biotechnol 2011, 163:895-905.
19. Dreborg S. The skin prick test in the diagnosis of atopic allergy. J Am Acad Dermatol 1989, 21:820-821.
20. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
21. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
22. Sarzehi S., Chamani J. Investigation on the interaction between tamoxifen and human holo-transferrin: determination of the binding mechanism by fluorescence quenching, resonance light scattering and circular dichroism methods. Int J Biol Macromol 2010, 47:558-569.
23. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
24. Batanero E., Barral P., Villalba M., Rodriguez R. Sensitization of mice with olive pollen allergen Ole e 1 induces a Th2 response. Int Arch Allergy Immunol 2002, 127:269-275.
25. Becker W.M., Vogel L., Vieths S. Standardization of allergen extracts for immunotherapy: where do we stand. Curr Opin Allergy Clin Immunol 2006, 6:470-475.
26. Lowenstein H., Larsen J.N. Recombinant allergens/allergen standardization. Curr Allergy Asthma Rep 2001, 1:474-479.
27. Nelson H.S. Allergen immunotherapy: where is it now. J Allergy Clin Immunol 2007, 119:769-779.
28. Linhart B., Jahn-Schmid B., Verdino P., Keller W., Ebner C., Kraft D., et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 2002, 16:1301-1303.
29. Kleber-Janke T., Becker W.M. Use of modified BL21(DE3) Escherichia coli cells for high-level expression of recombinant peanut allergens affected by poor codon usage. Protein Expr Purif 2000, 19:419-424.
30. Assarehzadegan M.A., Amini A., Sankian M., Tehrani M., Jabbari F., Varasteh A. Sal k 4, a new allergen of Salsola kali, is profilin: a predictive value of conserved conformational regions in cross-reactivity with other plant-derived profilins. Biosci Biotechnol Biochem 2010, 74:1441-1446.
31. Tehrani M., Sankian M., Assarehzadegan M.A., Falak R., Jabbari F., Varasteh A. Immunochemical characterization of Amaranthus retroflexus pollen extract: extensive cross-reactive allergenic components among the four species of Amaranthaceae/Chenopodiaceae. Iran J Allergy Asthma Immunol 2010, 9:87-95.
32. Nouri H.R., Sankian M., Vahedi F., Afsharzadeh D., Rouzbeh L., Moghadam M., et al. Diagnosis of Chenopodium album allergy with a cocktail of recombinant allergens as a tool for component-resolved diagnosis. Mol Biol Rep 2012, 39:3169-3178.
33. Valenta R., Kraft D. Recombinant allergen molecules: tools to study effector cell activation. Immunol Rev 2001, 179:119-127.
34. Reese G., Ballmer-Weber B.K., Wangorsch A., Randow S., Vieths S. Allergenicity and antigenicity of wild-type and mutant, monomeric, and dimeric carrot major allergen Dau c 1: destruction of conformation, not oligomerization, is the roadmap to save allergen vaccines. J Allergy Clin Immunol 2007, 119:944-951.